جستجوی استاد راهنمای دانشگاهی

Jennifer Golden is an Associate Professor in the Department of Pharmaceutical Sciences at the School of Pharmacy , University of Wisconsin-Madison . Her research focuses on synthetic medicinal chemistry to develop novel antiviral and anti-parasitic agents for diseases like alphavirus infections and kinetoplastid parasites. The Golden Lab emphasizes chemical methodology development and structure-activity relationship analysis through collaborations assessing compound efficacy in cell and animal models . Research Projects Quinazolinone Rearrangement: Developing synthetic transformations for amidine formation and ring-fused scaffolds. Anti-Alphaviral Agents: Creating FDA-approved therapeutic candidates for mosquito-borne RNA viruses. Broad-Spectrum Antiparasitics: Optimizing compounds for malaria, African sleeping sickness, and leishmaniasis. Publications highlight her work on ML336 (anti-VEEV), quinazolinone derivatives , and collaborations with experts in high-throughput screening and structural biology . Her lab trains students in hit-to-lead optimization , regioselective synthesis , and medicinal chemistry tactics . Education: B.S. (1996) – Eastern Illinois University Ph.D. (2002) – University of Kansas Postdoctoral Research (2004) – Stanford University

• Synthetic Medicinal Chemistry
• Antiviral Drug Development
• Antiparasitic Drug Discovery
• +۳ مورد دیگر

Dr. Philip A. Rea is a Professor of Biology and Rebecka and Arie Belldegrun Distinguished Director of the Life Sciences & Management Program at the University of Pennsylvania's School of Arts and Sciences. With over 100 publications and two co-authored books, his work spans fundamental biochemical research and science communication, focusing on life sciences implementation challenges. Education: D.Sc. (2020) and D.Phil. in Plant Biochemistry (University of Oxford), B.Sc. First Class Honors in Biological Sciences (University of Sussex) Dr. Rea's research explores transport phenomena and cellular detoxification, including vacuolar proton pumps and ABC transporters in plants, yeast, and nematodes. His work has significant applications in phytoremediation and combating parasitic diseases. His recent publications and book Managing Discovery in the Life Sciences (2018) analyze the transition from laboratory discovery to market success through case studies like statins, ivermectin, and metformin. These works highlight serendipity in biomedical innovation and investor-driven discovery management. Scientific Awards: Jesse H. Neal Award (2025) for technical/scientific content AAAS Fellow (2013) for membrane transport research National Academies Cozzarelli Prize (2010) for original research Multiple teaching honors including Lindback Foundation Award (2014) and Ira H. Abrams Award (2009) Society for Experimental Biology President's Medal (1990) Teaching: Proseminar in Management and the Life Sciences (LSMP 1210) Biochemistry (BIOL 2810) Focus on problem-solving with incomplete datasets

• Biochemistry
• Plant Biology
• Science Communication
• +۷ مورد دیگر

Marvin Meyers is a Professor of Chemistry and holds the Kranz Professorship for Excellence in Research at the School of Science and Engineering, Saint Louis University. He leads the Meyers Lab, focused on discovering novel drug candidates for neglected and infectious diseases, particularly antifungals and antiparasitics. His research integrates synthetic organic chemistry, medicinal chemistry, and structure-based drug design to optimize drug candidates' potency, pharmacokinetics, and safety. Educated at Dordt College (B.A., 1996) and the University of Illinois at Urbana-Champaign (Ph.D., 2000), Meyers teaches courses including CHEM 3100, CHEM 3970, and CHEM 4470/5470. His lab emphasizes undergraduate and graduate training in organic synthesis and drug discovery, with students contributing to publications and potential patent applications. Key research interests include drug repurposing (e.g., antifungal phenothiazines), antimalarial agents, and treatments for Cryptosporidium and hepatitis B virus. Collaborations with biologists and computational chemists drive discoveries in molecular pathways and drug targets. The lab's recent work includes antifungal mefloquine analogs (2024), fluorinated triazolopyridazines (2023), and HBV ribonuclease H inhibitors (2021). Meyers' lab is located in Monsanto Hall, and further details are available via www.meyerschemlab.com .

• Medicinal Chemistry
• Synthetic Organic Chemistry
• Chemical Biology
• +۴ مورد دیگر

Peter Schultz, PhD, is the President and CEO of Scripps Research, holding the L.S. “Sam” Skaggs Presidential Chair in the Department of Chemistry. He has been a faculty member since 1999, previously at UC Berkeley. His research spans synthetic biology, genetic code expansion, and drug discovery, with a focus on engineering organisms and molecules for biological and medical applications. Education: Ph.D. in Chemistry, California Institute of Technology (1984) B.S. in Chemistry, California Institute of Technology (1979) Research Interests: Expanding genetic codes to incorporate noncanonical amino acids in organisms Engineering endosymbiotic systems to study mitochondrial evolution Developing small molecules for cancer, stem cell therapies, and neglected diseases Designing antibodies and CAR-T cells for targeted therapies Article Trends: Recent work emphasizes small molecule therapies for cancer and fibrosis, synthetic biology applications in endosymbiosis, and genetic code expansion for protein engineering. Key themes include drug repurposing, targeted drug delivery, and molecular mechanisms of biological systems. Awards: Wolf Prize in Chemistry (1994) National Academy of Sciences Member (1993) Paul Ehrlich-and Ludwig Darmstaedter Prize (2002) National Academy of Inventors Fellow (2015) Advising & Grants: Supervises ~15 graduate students and postdocs annually. Secured funding from NSF, NIH, and industry partnerships. Over 85 former students hold academic positions globally. Labs/Teams: Heads the Schultz Lab at the Chi-Huey Wong Laboratories, focusing on biologically inspired synthesis and translational research.

• Biological Chemistry
• Genetic Code Expansion
• Stem Cell Biology
• +۳ مورد دیگر

Derek S. Tan is a Professor in the Department of Biochemistry and Biophysics at Weill Cornell Medical College, holding a Tri-Institutional Professor position effective from 2025. His research integrates chemical synthesis with biological applications, focusing on drug discovery, enzyme mechanisms, and therapeutic engineering. He maintains an active research program with continuous NIH funding. Education: Ph.D., Harvard University (2000) B.S., Stanford University (1995) Research Focus: Professor Tan's work spans chemical biology, medicinal chemistry, and microbiology. He designs bioactive molecules targeting bacterial permeability, enzyme inhibition, and cellular therapeutics. Key areas include ubiquitin pathway biochemistry, antibiotic development against Mycobacterium tuberculosis and Plasmodium falciparum , and engineered T-cell therapies for cancer. His interdisciplinary approach bridges synthetic chemistry with translational applications. Publication Trends: Recent articles (2021-2024) demonstrate three primary themes: 1) Development of mechanistic probes for enzyme systems (ubiquitin pathway, aminoacyl-tRNA synthetases), 2) Antibacterial/antiparasitic agent design leveraging bacterial permeability studies, and 3) Cellular engineering strategies including CAR-T micropharmacies for targeted drug activation. The work consistently combines synthetic chemistry innovation with biological validation. Grants: As Principal Investigator of the Tri-institutional PhD Program in Chemical Biology (NIH/NIGMS funded), he leads initiatives spanning 2020-2025 and 2025-2030. This underscores sustained commitment to interdisciplinary training at the chemistry-biology interface.

• Chemical Biology
• Medicinal Chemistry
• Biochemistry
• +۳ مورد دیگر

Karen S. Anderson is a Professor of Pharmacology and Molecular Biophysics and Biochemistry at Yale School of Medicine, with a primary appointment in the Department of Pharmacology. She serves as Co-Leader of Developmental Therapeutics at Yale Cancer Center and Co-Director of the Therapeutics/Chemotherapy Program. Dr. Anderson is also an undergraduate research mentor and fellow at Pierson College at Yale, where she advises freshman students. Dr. Anderson's research program focuses on mechanistic enzymology and structure-based drug design to develop novel therapeutics. Her work centers on understanding molecular mechanisms of enzymes that play critical roles in cancer and infectious diseases, including HIV/AIDS. She has made significant contributions to the understanding of HIV reverse transcriptase, anticancer targets like EGFR and HER-2, and enzymes involved in parasitic infections. Her laboratory employs a multidisciplinary approach combining biophysical techniques, structural studies, and computational methods to advance drug discovery. Analysis of her recent publications (2023-2025) reveals a strong research trajectory spanning three main areas: HIV drug resistance and novel inhibitors, cancer therapeutics focusing on resistance mechanisms and targeted therapies, and antiviral/antimicrobial drug development including work on SARS-CoV-2. Her research demonstrates consistent innovation in structure-based drug design approaches across multiple disease areas. Selected Awards and Honors: Enzymes, Coenzymes, & Metabolic Pathways Gordon Research Conference Chair (2001) Yale Cancer Breast Cancer Initiative Research Award (1996) Dean's Young Faculty Award from Yale University (1991) Multiple Monsanto Research Achievement Awards (1985-1989) YWCA Women's Leadership Award (1986-1987) Dr. Anderson has trained over 50 undergraduates, graduate students, M.D./Ph.D. students and postdoctoral fellows who have gone on to successful careers in academia and industry. Her laboratory, the Anderson Lab, focuses on translating mechanistic and structural studies into novel therapeutic approaches for viral infections and cancer. The lab utilizes a range of biophysical techniques to study clinically relevant proteins with the goal of developing more effective therapies for conditions including cancer, infectious diseases, and neurodegenerative disorders.

• Pharmacology
• Molecular Biophysics
• Biochemistry
• +۸ مورد دیگر

Dr. Mostafa Elfawal is an Assistant Professor at UMass Chan Medical School in the Program in Molecular Medicine, affiliated with the T.H. Chan School of Medicine. His research focuses on developing novel therapeutics against parasitic infections, particularly targeting soil-transmitted helminths and malaria. He completed his PhD in Medical Entomology/Microbiology at the University of Massachusetts Amherst, following a BA and MS in Animal Science from Ain Shams University in Egypt. His work emphasizes high-throughput drug screening and repurposing existing compounds for anthelmintic use, with recent breakthroughs in PIM kinase inhibitors and broad-spectrum antiparasitic agents. He has extensively studied Artemisia annua's antimalarial properties and its role in overcoming drug resistance. Collaborations with institutions like the NIH and international networks highlight his global impact in parasitology and tropical medicine. Key contributions include identifying metabolic enzyme inhibitors as anthelmintics, elucidating hookworm's cognitive and microbiome effects, and advancing yeast particle encapsulation for controlled drug release. His research bridges basic science with clinical application, addressing critical gaps in treating neglected tropical diseases.

• Parasitic Nematode Drug Development
• Antimicrobial Therapeutics
• Medical Entomology
• +۳ مورد دیگر

Valery Fokin is a Professor of Chemistry at the University of Southern California (USC), Department of Chemistry. His research focuses on organic synthesis with applications in chemical biology, particularly in click chemistry, antidote development, and bioconjugation. He holds a Ph.D. from USC (1998) and has contributed extensively to the design of novel synthetic methods and bioactive molecules. His work spans drug discovery, catalysis, and the development of reagents for toxicology applications. Notable contributions include advancements in azide-alkyne cycloaddition (CuAAC) and sulfur fluoride exchange (SuFEx) reactions, which have broad implications in medicinal chemistry and materials science. His lab explores strategies to create efficient organophosphate antidotes and antimicrobial agents targeting drug-resistant pathogens. Publications highlight innovations in microdroplet chemistry, enzyme reactivation mechanisms, and the synthesis of heterocyclic compounds. Fokin’s research bridges academic and industrial collaboration, as seen in studies on cannabinoid-derived drug potential and scalable synthesis methods. His team actively pursues applications in drug delivery and tissue-specific targeting. While no specific awards or grants are listed, his prolific publication record reflects sustained contributions to chemical biology. His advising and lab activities emphasize interdisciplinary approaches to solving biomedical challenges through innovative organic synthesis.

• Organic Chemistry
• Chemical Biology
• Drug Discovery
• +۵ مورد دیگر

Scott E. Schaus is a Professor of Organic and Medicinal Chemistry at Boston University. He leads the Schaus Group, focusing on enantioselective catalytic methodologies and biomedical research. His work spans development of novel synthetic techniques, including boronate catalysis and asymmetric Mannich reactions, as well as translational science targeting cancer and neglected tropical diseases. Collaborations with the Boston University Center for Molecular Discovery (CMD-BU) drive advancements in chemical library synthesis and drug discovery. Education: B.A. in Chemistry (Boston University, 1995; summa cum laude), Ph.D. in Organic Chemistry (Harvard University, 1999) Research: Specializes in catalytic asymmetric synthesis, natural product construction, and antiparasitic/anticancer drug development. Notable projects include liver cancer treatments with Prof. Ulla Hansen and work on Chagas disease. His lab has produced 20 Ph.D. graduates and 3 postdocs since 2001, with alumni in academia, pharmaceutical R&D, and industry. Current interests include expanding catalytic methodologies and applying chemical synthesis to biomedical challenges. The Schaus Group actively explores small molecule inhibitors, with a focus on LSF transcription factor pathways and antiviral agents.

• Organic Chemistry
• Medicinal Chemistry
• Catalytic Synthesis
• +۳ مورد دیگر

Dr. Ana C. Vallor is an Associate Professor of Biology at the University of the Incarnate Word (UIW), tenured since 2014. She holds a Ph.D. in Molecular Virology and Microbiology from the University of Pittsburgh (2002) and a B.S. in Biology from St. Mary’s University (1990). Her research focuses on antimicrobial discovery, probiotic applications, and microbial transmission dynamics, with recent work emphasizing drug biotransformation and soil-derived antimicrobial compounds. Dr. Vallor has authored/co-authored over 30 peer-reviewed publications and actively mentors undergraduate and graduate students in laboratory research. Academic leadership roles include Director of the Masters of Biology Program (2016–2018), Microbiology Course Coordinator, and service on institutional review boards. She is a member of SACNAS, ASM, and the San Antonio Center for Medical Mycology. Notable awards include the Presidential Teaching Legacy Award (2015) and the Sr. Joseph Marie Armer CCVI Endowed Chair (2019–2021). Her research explores novel antimicrobial agents from South Texas soil microorganisms, probiotic Lactobacillus species’ roles in pathogen inhibition, and fungal drug metabolism. Recent projects include HPLC analysis of antifungal biotransformation products and assessment of essential oils’ antibacterial efficacy. Dr. Vallor also leads educational outreach initiatives through programs like Tiny Earth and Upward Bound.

• Medical Microbiology
• Antimicrobial Drug Discovery
• Probiotics and Microbial Ecology
• +۴ مورد دیگر

Michael Pollastri serves as Senior Vice Provost and Academic Lead of the Roux Institute at Northeastern University, overseeing academic and research initiatives. He joined Northeastern's Department of Chemistry and Chemical Biology in 2009, became department chair in 2015, attained full professorship in 2017, and served as interim dean of the College of Science from March 2019. His academic journey began with a master's degree from Duke University, followed by a doctorate developed through a unique partnership between Pfizer and Brown University's Department of Chemistry. Duke University: Master's degree Brown University/Pfizer: Doctorate Pollastri's research centers on medicinal chemistry and drug discovery for neglected tropical diseases , with emphasis on human African trypanosomiasis, Chagas disease, and leishmaniasis. His work pioneers kinase inhibitor repurposing , multiparameter compound optimization , and structure-activity relationship studies to develop novel antiparasitic therapeutics. He integrates high-throughput screening with lead optimization strategies to address critical unmet medical needs in resource-limited settings. Analysis of his recent publications (2021-2025) reveals consistent focus on optimizing quinazolines, azaindoles, and carbazole derivatives against kinetoplastid parasites. His work demonstrates systematic progression from hit identification to lead optimization, with particular attention to physicochemical properties, target specificity, and broad-spectrum activity against trypanosomatid pathogens. During his tenure at Boston University (2007-2009), Pollastri established the Center for Molecular Discovery—a collaborative resource integrating high-throughput screening and medicinal chemistry capabilities. This initiative exemplifies his commitment to building infrastructure for antiparasitic drug discovery through academic-industry partnerships.

• Neglected Tropical Diseases
• Drug Discovery
• Medicinal Chemistry
• +۳ مورد دیگر

Karen Anderson, PhD, is a Professor of Pharmacology and Molecular Biophysics and Biochemistry at Yale School of Medicine. She serves as Co-Leader of the Developmental Therapeutics Program at Yale Cancer Center and Co-Director of the Therapeutics/Chemotherapy Program. Her research focuses on mechanistic enzymology and structure-based drug design to develop therapies for cancer, infectious diseases (e.g., HIV/AIDS), and antimicrobial targets. She has trained over 50 students across undergraduate, graduate, and postdoctoral levels. Educational Background: PhD from Ohio State University (1982), Senior Research Specialist at Monsanto Co. (1989). Research Interests: HIV reverse transcriptase mechanisms, antiviral agents, drug resistance, enzyme inhibitors for cancer and infectious diseases, and translational drug development. Key targets include KDO8P synthase (antibacterial), TS-DHFR (antiparasitic), and tyrosine kinase inhibitors (cancer). Awards & Honors: Dean's Young Faculty Award (1991), Yale Cancer Breast Cancer Initiative Award (1996), Gordon Research Conference leadership (2000-2001), and multiple Monsanto Research Achievement Awards (1985-1989). Grants & Collaborations: Leads interdisciplinary teams at Yale Cancer Center and collaborates with researchers like William Jorgensen on drug design. Her lab's work includes developing synergistic therapies for bladder cancer and alternatives to Paxlovid for SARS-CoV-2. Labs & Teams: Anderson Lab at Yale, part of the Structural Biology and Virology Laboratories programs. Active in initiatives like the Yale-UPR HIV Research Collaboration.

• Pharmacology
• Molecular Biology
• Antiviral Agents
• +۵ مورد دیگر

Manuel Llinás is the Ernest C. Pollard Professor in Biotechnology and Professor of Biochemistry and Molecular Biology and Chemistry at The Pennsylvania State University. His research focuses on understanding the molecular mechanisms of gene regulation and metabolism in the malaria parasite Plasmodium falciparum using functional genomics and metabolomics. Key areas include transcriptional regulation via ApiAP2 proteins and Plasmodium metabolomics to identify drug targets. Affiliations: Center for Eukaryotic Gene Regulation, Center for Infectious Disease Dynamics, Center for Malaria Research. Research Interests: Gene regulation, parasite metabolism, antimalarial drug discovery. His lab combines functional genomics, molecular biology, and metabolomics to study Plasmodium's developmental stages (blood, liver, mosquito). Recent work highlights chromatin remodeling factors (e.g., Snf2L) and ApiAP2 proteins as critical regulators. Metabolomic studies revealed unique metabolic pathways, including acetyl-CoA biosynthesis and red blood cell interactions. Publications emphasize multistage antimalarial compounds targeting ApiAP2 proteins and metabolic vulnerabilities. Awards include AAAS and ASTMH Fellowships and the Penn State Faculty Scholar Medal. Lab activities involve training graduate students (e.g., Alan Brown, Emma Hutchinson) and leveraging metabolomics and CRISPR tools. Current projects focus on drug targets in transcriptional networks and metabolic pathways.

• Malaria Research
• Gene Regulation
• Metabolomics
• +۷ مورد دیگر

Jonathan L Vennerstrom, PhD is a Professor in the Department of Pharmaceutical Sciences at the University of Nebraska Medical Center (UNMC) College of Pharmacy. His academic career spans over two decades with continuous research activity documented from 2002 through 2025. Dr. Vennerstrom's research focuses on antiparasitic drug discovery with particular emphasis on antimalarial drug design and synthesis and the investigation of heme as a mechanistic intersection for antimalarial drugs. His laboratory currently pursues drug discovery for schistosomiasis , cytomegalovirus , and tuberculosis . Recent publications demonstrate significant contributions to medium-ring keto lactams, diaryl ureas, and tetrahydro-γ-carboline sulfonamides as promising antiparasitic chemotypes. His publication record shows consistent output with over 100 publications since 2002, including high-impact articles in journals like ACS Infectious Diseases and Journal of Medicinal Chemistry. The research demonstrates strong focus on antischistosomal compounds antimalarial mechanisms novel heterocyclic synthesis parasite-specific drug targeting At UNMC, Dr. Vennerstrom serves as course coordinator for Medicinal Chemistry I and II in the professional pharmacy curriculum and teaches Advanced Medicinal Chemistry at the graduate level. His teaching directly supports the educational mission of the College of Pharmacy through integration of cutting-edge research into classroom instruction.

• Antiparasitic Drug Discovery
• Antimalarial Drug Design
• Schistosomiasis Research
• +۴ مورد دیگر

Jason Sello is a Professor in the Department of Pharmaceutical Chemistry at the University of California San Francisco (UCSF), holding roles as Vice Dean of Academic Affairs and Executive Committee Member. His research focuses on bacterial proteins, antibiotic resistance mechanisms, and natural product synthesis, particularly targeting pathogens like Mycobacterium tuberculosis and Candida species. He leads efforts in developing proteasome inhibitors and novel antibacterial agents through multidisciplinary approaches. Key affiliations include the Quantitative Biosciences Institute (QBI) and the Chan Zuckerberg Biohub. His work spans chemical synthesis, microbial genetics, and drug discovery, with contributions to understanding efflux pump mechanisms and retrograde trafficking inhibitors. Notable achievements include the synthesis of cyclomarin natural products and the development of small molecules restoring antifungal efficacy against drug-resistant Candida strains. His research integrates organic chemistry, microbiology, and pharmacology, addressing challenges in antibiotic resistance and drug delivery. Recent publications highlight in vivo approaches for neuroactive molecules and the mechanistic study of ClpP proteases in tuberculosis. Sello also contributes to institutional leadership, including equity initiatives in pharmacy education and diversity outreach programs.

• Bacterial Proteins
• Mycobacterium tuberculosis
• Proteasome Inhibitors
• +۳ مورد دیگر